Rajeev K Tyagi
Augusta University, USA
Title: Co-administration of Methotrexate and Aceclofenac shows synergistic effect on rheumatoid arthritis when delivered through lipid nanocarriers
Biography
Biography: Rajeev K Tyagi
Abstract
Methotrextae (MTX), a potent disease modifying anti-rheumatic drug (DMARDs)
and aceclofenac (ACE) a well-known NSAIDs, are widely used drugs for the
treatment of rheumatoid arthritis. MTX and ACE were encapsulated in wellcharacterized
lipid polymer hybrid Nanoparticles (LPHNPs) and nanostructured
lipid carriers (NLCs) respectively. The efficiency of both drugs as mono- and cotherapy
was assessed in lipopolysaccharide (LPS) treated and inflammation
mimicked human monocytic (U937) cells. The efficiency of these drugs was
confirmed by the estimation of surface inflammatory biomarkers
(Immunocytochemistry) as well as transcript (RT-PCR), proteome (western blot),
and histopathology. The ex-vivo results were corroborated by the results
obtained in an experimentally induced (complete Freund’s adjuvant
supplemented with mycobacterium tuberculosis animal model) arthritis animal
model. Our results present co-administration therapy (administration of MTX
and ACE via LPHNPs & NLCs through intravenous and transdermal route,
respectively) as an efficient therapeutic approach to treat rheumatoid arthritis.
We have compared the market formulations of ACE gel and MTX administered
through transdermal and subcutaneous route. Collectively, our results show
the administration of developed combination drug delivery systems which may
efficiently augment the enrichment of both drugs at the site of arthritis which
in turn prodigiously suppresses the arthritis growth.